Sierra Capital LLC Buys Shares of 12,500 Pacira BioSciences, Inc. $PCRX

Sierra Capital LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 12,500 shares of the company’s stock, valued at approximately $299,000.

Several other institutional investors have also recently made changes to their positions in the company. Doma Perpetual Capital Management LLC raised its holdings in shares of Pacira BioSciences by 3.2% in the first quarter. Doma Perpetual Capital Management LLC now owns 1,804,069 shares of the company’s stock valued at $44,831,000 after acquiring an additional 56,220 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Pacira BioSciences during the 1st quarter valued at about $32,506,000. Geode Capital Management LLC raised its holdings in shares of Pacira BioSciences by 0.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,143,190 shares of the company’s stock valued at $27,326,000 after purchasing an additional 5,658 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Pacira BioSciences by 49.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock worth $27,454,000 after purchasing an additional 367,869 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Pacira BioSciences by 88.3% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 855,488 shares of the company’s stock worth $21,259,000 after purchasing an additional 401,227 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Trading Up 0.7%

NASDAQ PCRX opened at $23.78 on Monday. Pacira BioSciences, Inc. has a 12-month low of $16.00 and a 12-month high of $27.64. The company has a fifty day simple moving average of $23.93 and a two-hundred day simple moving average of $24.34. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50. The stock has a market cap of $1.02 billion, a P/E ratio of -8.55 and a beta of 0.36.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. The firm had revenue of $179.52 million for the quarter, compared to analyst estimates of $182.86 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The business’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.79 earnings per share. Pacira BioSciences has set its FY 2025 guidance at EPS. On average, analysts forecast that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.

Wall Street Analyst Weigh In

PCRX has been the topic of several research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Pacira BioSciences in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Monday. Truist Financial reduced their price target on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Finally, Wall Street Zen upgraded Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $27.60.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.